273 related articles for article (PubMed ID: 11966407)
1. Novel insulin sensitizers: pharmacogenomic aspects.
Otto C; Lehrke M; Göke B
Pharmacogenomics; 2002 Jan; 3(1):99-116. PubMed ID: 11966407
[TBL] [Abstract][Full Text] [Related]
2. [Mechanisms of action of thiazolidinediones].
Girard J
Diabetes Metab; 2001 Apr; 27(2 Pt 2):271-8. PubMed ID: 11452221
[TBL] [Abstract][Full Text] [Related]
3. Glitazones: clinical effects and molecular mechanisms.
Stumvoll M; Häring HU
Ann Med; 2002; 34(3):217-24. PubMed ID: 12173692
[TBL] [Abstract][Full Text] [Related]
4. Metabolic and additional vascular effects of thiazolidinediones.
Martens FM; Visseren FL; Lemay J; de Koning EJ; Rabelink TJ
Drugs; 2002; 62(10):1463-80. PubMed ID: 12093315
[TBL] [Abstract][Full Text] [Related]
5. [Thiazolidinediones in type 2 diabetes. Role of peroxisome proliferator-activated receptor gamma (PPARgamma)].
Dubois M; Vantyghem MC; Schoonjans K; Pattou F
Ann Endocrinol (Paris); 2002 Dec; 63(6 Pt 1):511-23. PubMed ID: 12527853
[TBL] [Abstract][Full Text] [Related]
6. [Glitazones (thiazolidinedione)].
Ducobu J; Sternon J
Rev Med Brux; 2000 Oct; 21(5):441-6. PubMed ID: 11109896
[TBL] [Abstract][Full Text] [Related]
7. Troglitazone and related compounds: therapeutic potential beyond diabetes.
Fujiwara T; Horikoshi H
Life Sci; 2000 Oct; 67(20):2405-16. PubMed ID: 11065164
[TBL] [Abstract][Full Text] [Related]
8. A new thiazolidinedione, NC-2100, which is a weak PPAR-gamma activator, exhibits potent antidiabetic effects and induces uncoupling protein 1 in white adipose tissue of KKAy obese mice.
Fukui Y; Masui S; Osada S; Umesono K; Motojima K
Diabetes; 2000 May; 49(5):759-67. PubMed ID: 10905484
[TBL] [Abstract][Full Text] [Related]
9. [PPARgamma and insulin resistance].
Girard J
Ann Endocrinol (Paris); 2002 Apr; 63(2 Pt 2):1S19-22. PubMed ID: 12037503
[TBL] [Abstract][Full Text] [Related]
10. [Mechanisms of thiazolidinedione derivatives for hypoglycemic and insulin sensitizing effects].
Sugiyama Y; Murase K; Ikeda H
Nihon Rinsho; 2000 Feb; 58(2):370-5. PubMed ID: 10707560
[TBL] [Abstract][Full Text] [Related]
11. Experimental approaches to study PPAR gamma agonists as antidiabetic drugs.
Vázquez M; Silvestre JS; Prous JR
Methods Find Exp Clin Pharmacol; 2002 Oct; 24(8):515-23. PubMed ID: 12500431
[TBL] [Abstract][Full Text] [Related]
12. Differential activation of peroxisome proliferator-activated receptor-gamma by troglitazone and rosiglitazone.
Camp HS; Li O; Wise SC; Hong YH; Frankowski CL; Shen X; Vanbogelen R; Leff T
Diabetes; 2000 Apr; 49(4):539-47. PubMed ID: 10871190
[TBL] [Abstract][Full Text] [Related]
13. Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone.
Sakamoto J; Kimura H; Moriyama S; Odaka H; Momose Y; Sugiyama Y; Sawada H
Biochem Biophys Res Commun; 2000 Nov; 278(3):704-11. PubMed ID: 11095972
[TBL] [Abstract][Full Text] [Related]
14. Novel genes regulated by the insulin sensitizer rosiglitazone during adipocyte differentiation.
Albrektsen T; Frederiksen KS; Holmes WE; Boel E; Taylor K; Fleckner J
Diabetes; 2002 Apr; 51(4):1042-51. PubMed ID: 11916924
[TBL] [Abstract][Full Text] [Related]
15. Hypertension and insulin resistance: role of peroxisome proliferator-activated receptor gamma.
Itoh H; Doi K; Tanaka T; Fukunaga Y; Hosoda K; Inoue G; Nishimura H; Yoshimasa Y; Yamori Y; Nakao K
Clin Exp Pharmacol Physiol; 1999 Jul; 26(7):558-60. PubMed ID: 10405788
[TBL] [Abstract][Full Text] [Related]
16. 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma.
Forman BM; Tontonoz P; Chen J; Brun RP; Spiegelman BM; Evans RM
Cell; 1995 Dec; 83(5):803-12. PubMed ID: 8521497
[TBL] [Abstract][Full Text] [Related]
17. Thiazolidinediones produce a conformational change in peroxisomal proliferator-activated receptor-gamma: binding and activation correlate with antidiabetic actions in db/db mice.
Berger J; Bailey P; Biswas C; Cullinan CA; Doebber TW; Hayes NS; Saperstein R; Smith RG; Leibowitz MD
Endocrinology; 1996 Oct; 137(10):4189-95. PubMed ID: 8828476
[TBL] [Abstract][Full Text] [Related]
18. A new selective peroxisome proliferator-activated receptor gamma antagonist with antiobesity and antidiabetic activity.
Rieusset J; Touri F; Michalik L; Escher P; Desvergne B; Niesor E; Wahli W
Mol Endocrinol; 2002 Nov; 16(11):2628-44. PubMed ID: 12403851
[TBL] [Abstract][Full Text] [Related]
19. Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro.
Galli A; Crabb DW; Ceni E; Salzano R; Mello T; Svegliati-Baroni G; Ridolfi F; Trozzi L; Surrenti C; Casini A
Gastroenterology; 2002 Jun; 122(7):1924-40. PubMed ID: 12055599
[TBL] [Abstract][Full Text] [Related]
20. Potentiation of glucose uptake in 3T3-L1 adipocytes by PPAR gamma agonists is maintained in cells expressing a PPAR gamma dominant-negative mutant: evidence for selectivity in the downstream responses to PPAR gamma activation.
Nugent C; Prins JB; Whitehead JP; Savage D; Wentworth JM; Chatterjee VK; O'Rahilly S
Mol Endocrinol; 2001 Oct; 15(10):1729-38. PubMed ID: 11579205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
